Dataset Information

Long-Term Oxygen Therapy and Risk of Fire-Related Events.

ABSTRACT: Introduction:Two large major trials showed that long-term oxygen therapy (LTOT) improved mortality in patients with chronic obstructive pulmonary disease (COPD) and hypoxemia. Although oxygen accelerates combustion and is an obvious fire hazard, LTOT has traditionally been prescribed to veterans who are actively smoking. Methods:We conducted a retrospective chart review of all veterans with COPD at a single center who were prescribed new LTOT between October 2010 and September 2015. Of the 158 patients who met the study criteria, 152 were male. Bayesian logistic regression was used to model the outcome variable fire-related incident with the predictors smoking status, age, race, depression, posttraumatic stress disorder, and type of oxygen used. Results:The mean age of the 158 patients with COPD in the study was 71.3 years in nonsmokers and 65.9 years in smokers. The model-estimated odds (SD) of a fire-related incident occurring in a smoker were 31.6 (5.1-372.7) times the odds of a fire-related incident occurring in a nonsmoker. Conclusions:Patients who smoke and remain on LTOT put themselves at greater risk of having a fire-related incident than do nonsmokers.

SUBMITTER: Moslander C

PROVIDER: S-EPMC7592901 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Long-Term Oxygen Therapy and Risk of Fire-Related Events.

Moslander Conner C Lat Tasnim T Giri Badri B Pattison Rachael R Coppin John D JD Bhat Udaya M UM

Federal practitioner : for the health care professionals of the VA, DoD, and PHS 20201001 10

<h4>Introduction</h4>Two large major trials showed that long-term oxygen therapy (LTOT) improved mortality in patients with chronic obstructive pulmonary disease (COPD) and hypoxemia. Although oxygen accelerates combustion and is an obvious fire hazard, LTOT has traditionally been prescribed to veterans who are actively smoking.<h4>Methods</h4>We conducted a retrospective chart review of all veterans with COPD at a single center who were prescribed new LTOT between October 2010 and September 201 ...[more]

PMID: 33132681

Similar Datasets

Project description:Chronic obstructive pulmonary disease (COPD) is a leading cause of death worldwide, and long-term oxygen therapy has been shown to reduce mortality in COPD patients with severe hypoxemia. However, the Long-term Oxygen Treatment Trial (LOTT), a large randomized trial, found no benefit of oxygen therapy in COPD patients with moderate hypoxemia. We hypothesized that there may be differences in response to oxygen which depend on genotype or gene expression. In a genome-wide time-to-event analysis of the primary outcome of death or hospitalization in 331 subjects, 97 single nucleotide polymorphisms (SNPs) showed evidence of interaction with oxygen therapy at P < 1e-5, including 7 SNPs near arylsulfatase B (ARSB; P = 6e-6). In microarray expression profiling on 51 whole blood samples from 37 individuals, at screening and/or at 12-month follow-up, ARSB expression was associated with the primary outcome depending on oxygen treatment. The significant SNPs were conditional expression quantitative trait loci for ARSB expression. In a network analysis of genes affected by long-term oxygen, two observed clusters including 26 co-expressed genes were enriched in mitochondrial function. Using data from the observational COPDGene Study, we validated the expression of 25 of these 26 genes, plus ARSB. The effect of long-term oxygen therapy in COPD varied based on ARSB expression and genotype. ARSB has previously been shown to be associated with hypoxemia in human bronchial and colonic epithelial cells and in a mouse model. In peripheral blood, long-term oxygen treatment affected expression of mitochondrial-related genes, a biologically relevant pathway in COPD. SNPs and expression of ARSB are associated with response to long-term oxygen in COPD. The ARSB SNPs were expression quantitative trait loci depending on oxygen therapy. Genes differentially expressed by long-term oxygen were enriched in mitochondrial functions. This suggests a potential biomarker to personalize use of long-term oxygen in COPD.

Project description:Estimates of the risk of recurrent cardiovascular events (residual risk) among patients with acute coronary syndromes have largely been based on clinical trial populations. Our objective was to estimate the residual risk associated with common comorbidities in a large, unselected, population-based cohort of acute coronary syndrome patients. 31,056 ACS patients (49.5%-non-ST segment elevation myocardial infarction [NSTEMI], 34.0%-ST segment elevation myocardial infarction [STEMI] and 16.5%-unstable angina [UA]) hospitalised in Alberta between April 2010 and March 2016 were included. The primary composite outcome was major adverse cardiovascular events (MACE) including: death, stroke or recurrent myocardial infarction. The secondary outcome was death from any cause. Cox-proportional hazard models were used to identify the impact of ACS type and commonly observed comorbidities (heart failure, hypertension, peripheral vascular disease, renal disease, cerebrovascular disease and diabetes). At 3.0 +/- 3.7 years, rates of MACE were highest in the NSTEMI population followed by STEMI and UA (3.58, 2.41 and 1.68 per 10,000 person years respectively). Mortality was also highest in the NSTEMI population followed by STEMI and UA (2.23, 1.38 and 0.95 per 10,000 person years respectively). Increased burden of comorbidities was associated with an increased risk of MACE, most prominently seen with heart failure (adjusted HR 1.83; 95% CI 1.73-1.93), renal disease (adjusted HR 1.52; 95% CI 1.40-1.65) and diabetes (adjusted HR 1.51; 95% CI 1.44-1.59). The cumulative presence of each of examined comorbidities was associated with an incremental increase in the rate of MACE ranging from 1.7 to 9.98 per 10,000 person years. Rates of secondary prevention medications at discharge were high including: statin (89.5%), angiotensin converting enzyme inhibitor/angiotensin receptor blocker (84.1%) and beta-blockers (85.9%). Residual cardiovascular risk following an acute coronary syndrome remains high despite advances in secondary prevention. A higher burden of comorbidities is associated with increased residual risk that may benefit from aggressive or novel therapies.

Dataset Information

Long-Term Oxygen Therapy and Risk of Fire-Related Events.

Publications

Long-Term Oxygen Therapy and Risk of Fire-Related Events.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets